San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant. Read More ›

Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for. Read More ›

Dr Erica Mayer discusses the positive results of the EMBER-3 trial, and the impact that imlunestrant will have on the treatment of patients with advanced breast cancer Read More ›

SIM0270, a new monotherapy treatment for advanced breast cancer, shows promising clinical activity and a manageable safety profile in a phase 1 clinical trial. Read More ›

SIM0270, a novel selective estrogen receptor degrader, combined with everolimus shows preliminary efficacy with a high rate of treatment-emergent adverse events at the recommended dose in treating patients with advanced breast cancer. Read More ›

Racial disparities are evident in the treatment and outcomes for patients with hormone receptor–positive/HER2-negative metastatic breast cancer in the United States. Read More ›

The ZEST study explored the potential of niraparib in treating early-stage breast cancer patients with detectable ctDNA, paving the way for future research on personalized treatment strategies based on ctDNA detection. Read More ›

Final analysis of the DAWNA-2 trial confirms the addition of dalpiciclib to endocrine therapy significantly improves progression-free survival in patients with hormone receptor–positive/HER2-negative advanced breast cancer. Read More ›

While artificial intelligence offers promising applications in healthcare, such as generating clinical summaries and estimating risks, its integration is hindered by limitations in EHR systems and the need for further model development Read More ›

A new study highlights the potential of serial liquid biopsies to monitor treatment response and uncover dynamic genomic changes in patients with metastatic breast cancer. Read More ›

Page 3 of 16

Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications